Results 61 to 70 of about 13,727 (197)

Principles of focused ultrasound [PDF]

, 2018
Focused ultrasound (FUS/HIFU) relies on ablation of pathological tissues, by delivering sufficiently high level of acoustic energy in situ of the human body. Magnetic Resonance guided FUS (MRgFUS/HIFU) and Ultrasound guided (USgFUS/HIFU) are image guided
Melzer, Andreas, Mihcin, Senay
core   +2 more sources

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

From ARB to ARNI in Cardiovascular Control [PDF]

, 2016
Coexistence of hypertension, diabetes mellitus and chronic kidney disease synergistically aggravates the risk of cardiovascular and renal morbidity and mortality.
Danser, A.H.J. (Jan), Hoorn, E.J. (Ewout), Roksnoer, L.C.W. (Lodi), Uijl, E. (Estrellita)   +3 more
core   +1 more source

Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction

ESC Heart Failure, 2021
Aims Sacubitril/valsartan combines renin–angiotensin–aldosterone system inhibition with amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides exert direct effects on pulmonary vasculature.
Jeffrey S. Tran, Ofer Havakuk, Jennifer M. McLeod, Jennifer Hwang, Hoi Yan Kwong, David Shavelle, Michael R. Zile, Uri Elkayam, Michael W. Fong, Luanda P. Grazette   +9 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. [PDF]

, 2016
AIMS: Heart failure (HF) treatment guided by physicians with access to real-time pressure measurement from a wireless implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF-related hospital admissions in ...
Abraham, Abraham, Adamson, Adamson, Berg, Boyne, Braunschweig, Briggs, Chaudhry, Cleland, Cleland, Cotter, Curtis, Drummond, Gheorghiade, Griffiths, Inglis, Jeon, Jhund, Kato, Klersy, Koehler, Martinson, Matza, Mitchell, Mosterd, Ong, Pandor, Ponikowski, Sandhu, Schiff, Thokala, Townsend   +32 more
core   +2 more sources

Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats

Clinical and Experimental Hypertension, 2019
Background: Sacubitril (SAC), a neprilysin inhibitor prevent degradation of neprilysin and activate cGMP signaling pathways leading to rise in blood volume concurrent to blood pressure by means of vasoactive peptides, adrenomedullin, and bradykinin ...
Mohd Imran, Md Quamrul Hassan, Md Sayeed Akhtar, Obaid Rahman, M. Akhtar, Abul Kalam Najmi   +5 more
doaj   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]

, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian, Desai, Akshay S, Lefkowitz, Martin, McMurray, John JV, Packer, Milton, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Rouleau, Jean, Shi, Victor, Solomon, Scott D, Swedberg, Karl, Teerlink, John R, Vardeny, Orly, Zile, Michael R   +12 more
core   +1 more source

Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. [PDF]

, 2019
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Agewall, S, Rosano, GM, Spoletini, I, Vitale, C   +3 more
core   +2 more sources